Biological therapy for lupus nephritis—tribulations and trials

[1]  I. Sanz,et al.  B cells as therapeutic targets in SLE , 2010, Nature Reviews Rheumatology.

[2]  P. Lipsky,et al.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. , 2010, Arthritis and rheumatism.

[3]  J. Levy,et al.  Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  C. Gordon,et al.  Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. , 2009, Rheumatology.

[5]  A. Sharabi,et al.  Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression. , 2009, Journal of autoimmunity.

[6]  M. Schneider,et al.  EULAR-Empfehlungen zur Behandlung des systemischen Lupus erythematodes , 2009, Zeitschrift für Rheumatologie.

[7]  I. Nestorov,et al.  An Exploratory Dose-Escalating Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Atacicept in Patients with Systemic Lupus Erythematosus , 2009, Lupus.

[8]  S. Bae,et al.  The Efficacy and Safety of Abatacept in SLE: Results of a 12-month Exploratory Study , 2008 .

[9]  D. Wallace,et al.  Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. , 2008, Arthritis and rheumatism.

[10]  Kerstin Amann,et al.  The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis , 2008, Nature Medicine.

[11]  J. Fechner,et al.  CD4+CD25+FOXP3+ Regulatory T Cells Increase De Novo in Kidney Transplant Patients After Immunodepletion with Campath‐1H , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  D. Isenberg,et al.  B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response , 2007 .

[13]  Kenneth G. C. Smith,et al.  B cells in glomerulonephritis: focus on lupus nephritis , 2007, Seminars in Immunopathology.

[14]  Andreas Radbruch,et al.  Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls , 2007, Annals of the rheumatic diseases.

[15]  J. Ioannidis,et al.  EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics , 2007, Annals of the rheumatic diseases.

[16]  G. Burmester,et al.  Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus , 2006, Arthritis research & therapy.

[17]  D. F. Barber,et al.  PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus , 2005, Nature Medicine.

[18]  C. Mok,et al.  Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. , 2005, Kidney international.

[19]  Y. Shoenfeld,et al.  Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. , 2004, Autoimmunity reviews.

[20]  C. Mojcik,et al.  Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus , 2004, Lupus.

[21]  F. Granath,et al.  Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. , 2004, The Journal of rheumatology.

[22]  V. Roschke,et al.  B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. , 2003, Arthritis and rheumatism.

[23]  W. Weng,et al.  Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Hughes,et al.  Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients , 2003, Medicine.

[25]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[26]  G. Illei,et al.  A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. , 2003, Arthritis and rheumatism.

[27]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  R. Bagin,et al.  LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. , 2003, Arthritis and rheumatism.

[29]  D. Wofsy,et al.  Cutting Edge: Reversal of Murine Lupus Nephritis with CTLA4Ig and Cyclophosphamide1 , 2001, The Journal of Immunology.

[30]  D. Lacey,et al.  Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Isenberg,et al.  B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. , 2008, Annals of the rheumatic diseases.